Announced
Completed
Financials
Tags
Biotechnology
Private Equity
Completed
Single Bidder
Friendly
Minority
United States
Private
biotech
Acquisition
Domestic
Synopsis
BVCF Management, a healthcare investment company, led a $15m Series A financing round in Cellenkos, a biotech company focused on developing transformative novel T regulatory (Treg) cell therapies to treat autoimmune and inflammatory disorders. "Cellenkos' innovative and transformative Treg cell therapy platform to address autoimmune and inflammatory disorders has the potential to significantly serve unmet patient needs. We are proud to lead the financing and support their groundbreaking efforts," Dr. Zhi Yang, BVCF Managing Partner.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.